文献速递临床试验与 GCP基础与转化研究组学、生物样本库与精准医学

阿司匹林干预降低结直肠癌风险(ASPIRED):一项随机对照试验的研究方案

ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2017-02-01

ASPIRED是一项前瞻性、双盲、多剂量、安慰剂对照的生物标志物临床试验,纳入既往诊断为结直肠腺瘤的个体180例,按1:1:1随机分配至低剂量阿司匹林81 mg/天、标准剂量325 mg/天或安慰剂组,以尿前列腺素代谢物PGE-M为主要终点,同时评估血浆炎症标志物、结肠基因表达、细胞纳米细胞学及口腔和肠道微生物组成与功能,旨在阐明阿司匹林降低结直肠癌风险的机制并探索基于机制的风险分层生物标志物。

要点

  • ASPIRED试验纳入既往结直肠腺瘤患者180例,随机分为阿司匹林81 mg/天、325 mg/天或安慰剂三组。
  • 主要终点为尿前列腺素代谢物PGE-M,同时评估血浆MIC-1、结肠TCF7L2与HPGD表达、细胞纳米细胞学及口腔和肠道微生物。
  • 试验旨在明确阿司匹林预防结直肠癌的机制及基于机制的风险分层生物标志物。

核心结论

  • 阿司匹林可能通过多种相互关联的机制预防结直肠癌,ASPIRED试验将审视这些通路并研究基于机制的风险分层生物标志物。

研究设计与样本

  • ASPIRED是一项前瞻性、双盲、多剂量、安慰剂对照的生物标志物临床试验,研究对象为既往诊断为结直肠腺瘤的个体。
  • 计划纳入180例个体,按1:1:1比例随机分配至低剂量阿司匹林81 mg/天、标准剂量阿司匹林325 mg/天或安慰剂组。
  • 在两次研究访视中收集生活方式、饮食和生物特征数据以及尿、唾液和血液标本;在无肠道准备的软式乙状结肠镜检查中收集粪便、肉眼正常的结直肠黏膜活检和细胞学刷检标本。

主要发现

  • 研究将检测阿司匹林对尿前列腺素代谢物PGE-M(主要终点)的影响。
  • 研究将检测阿司匹林对血浆炎症标志物巨噬细胞抑制性细胞因子-1(MIC-1)的影响。
  • 研究将检测阿司匹林对结肠转录因子结合(转录因子7样2(TCF7L2))表达的影响。
  • 研究将检测阿司匹林对结肠细胞基因表达的影响,包括羟基前列腺素脱氢酶15-(NAD)(HPGD)及编码Wnt信号蛋白的基因。
  • 研究将检测阿司匹林对结肠细胞纳米细胞学以及口腔和肠道微生物组成与功能的影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although aspirin is recommended for the prevention of colorectal cancer, the specific individuals for whom the benefits outweigh the risks are not clearly defined. Moreover, the precise mechanisms by which aspirin reduces the risk of cancer are unclear. We recently launched the ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED) trial to address these uncertainties. METHODS/DESIGN: ASPIRED is a prospective, double-blind, multidose, placebo-controlled, biomarker clinical trial of aspirin use in individuals previously diagnosed with colorectal adenoma. Individuals (n = 180) will be randomized in a 1:1:1 ratio to low-dose (81 mg/day) or standard-dose (325 mg/day) aspirin or placebo. At two study visits, participants will provide lifestyle, dietary and biometric data in addition to urine, saliva and blood specimens. Stool, grossly normal colorectal mucosal biopsies and cytology brushings will be collected during a flexible sigmoidoscopy without bowel preparation. The study will examine the effect of aspirin on urinary prostaglandin metabolites (PGE-M; primary endpoint), plasma inflammatory markers (macrophage inhibitory cytokine-1 (MIC-1)), colonic expression of transcription factor binding (transcription factor 7-like 2 (TCF7L2)), colonocyte gene expression, including hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD) and those that encode Wnt signaling proteins, colonic cellular nanocytology and oral and gut microbial composition and function. DISCUSSION: Aspirin may prevent colorectal cancer through multiple, interrelated mechanisms. The ASPIRED trial will scrutinize these pathways and investigate putative mechanistically based risk-stratification biomarkers. TRIAL REGISTRATION: This protocol is registered with the U.S. National Institutes of Health trial registry, ClinicalTrials.gov, under the identifier NCT02394769 . Registered on 16 March 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Drew DA, Chin SM, Gilpin KK, et al. ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial. Trials. 2017. PMID: 28143522. doi:10.1186/s13063-016-1744-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。